VNA
CTKB icon

Valley National Advisers’s Cytek Biosciences CTKB Stock Holding History

Valley National Advisers’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-120
Closed -$1K – 1228
2023
Q4 		$1K Buy
+120
New +$755 ﹤0.01% 1049

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Valley National Advisers's CTKB Position: Q1 2024 in Review

Valley National Advisers sold out of Cytek Biosciences (CTKB) in Q1 2024, closing a stake of 120 shares — an estimated $1K sold.

Valley National Advisers first reported a position in CTKB in Q4 2023 and held it in 1 quarter. The position peaked at $1K in Q4 2023. 125 funds tracked by Wall St. Rank hold CTKB as of Q1 2024.

  • Valley National Advisers reported no remaining Cytek Biosciences position as of Q1 2024 after selling out during the quarter.
  • Valley National Advisers sold 120 Cytek Biosciences shares in Q1 2024, an estimated $1K.
  • Valley National Advisers first reported a position in Cytek Biosciences in Q4 2023 and held it in 1 quarter.
  • Valley National Advisers's Cytek Biosciences position peaked at $1K in Q4 2023.
  • 125 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2024.

Based on Valley National Advisers's 13F filing for Q1 2024, filed 19 Apr 2024.